Johnson & Johnson Strengthens its Biosurgical Position by Acquiring Omrix
By Sally Mardikian PhD
Pharma Deals Review: Vol 2008 Issue 102 (Table of Contents)
Published: 24 Nov-2008
DOI: 10.3833/pdr.v2008.i102.111 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Johnson & Johnson (J&J) has gained a series of innovative biosurgical products with its acquisition of Omrix, its partner of five years, for US$438 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS